Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: An open-label randomized controlled trial
Olubukola T Idoko, Robert B Mboizi, Michael Okoye, France Laudat, Bubacarr Ceesay, John Z Liang, Natacha Le Dren-Narayanin, Kathrin U Jansen, Alejandra Gurtman, Kimberly J Center, Daniel A Scott, Beate Kampmann, Anna Roca, Olubukola T Idoko, Robert B Mboizi, Michael Okoye, France Laudat, Bubacarr Ceesay, John Z Liang, Natacha Le Dren-Narayanin, Kathrin U Jansen, Alejandra Gurtman, Kimberly J Center, Daniel A Scott, Beate Kampmann, Anna Roca
Abstract
Background: This open-label randomized controlled trial in infants compared safety, tolerability, and immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) formulated with the preservative 2-phenoxyethanol (2-PE) in a multidose vial (MDV) to the current PCV13 without 2-PE in a single-dose syringe (SDS).
Methods: Gambian infants were randomized 1:1 to receive PCV13 as either MDV or SDS at ages 2, 3, and 4months. Serotype-specific antipneumococcal antibody responses and opsonophagocytic activity ([OPA]; subset) were measured at age 5months. Noninferiority was declared if the lower bound of the 97.5% CI for the difference (MDV-SDS) in proportions of subjects achieving IgG concentrations ≥0.35μg/mL (primary endpoint) was greater than -10%. IgG geometric mean concentrations (GMCs) were noninferior if the lower limit of the two-sided 97.5% CI of the geometric mean ratio (MDV vs SDS) was greater than 0.5. Reactogenicity and other adverse events were collected.
Results: 500 participants were randomized and vaccinated; 489 (MDV: n=245; SDS: n=244) completed the trial. Noninferiority of MDV was demonstrated for all serotypes as measured by percentage of subjects achieving antibody responses above ≥0.35μg/mL. IgG GMCs (coprimary endpoint) also demonstrated noninferiority of MDV; OPA results supported these findings. Safety and tolerability were comparable between groups.
Conclusions: PCV13 in MDV was safe and immunogenic when administered according to the routine schedule to infants. MDV was noninferior to SDS for all 13 pneumococcal serotypes. Comparable immunogenicity and safety profiles of PCV13 MDV and SDS suggest PCV13 MDV can help optimize vaccination in resource-limited settings. ClinicalTrials.gov NCT01964716 https://ichgcp.net/clinical-trials-registry/NCT01964716.
Keywords: 2-Phenoxyethanol; Immunogenicity; Multidose vials; Pneumococcal conjugate vaccine; Safety.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Source: PubMed